Neoadjuvant Endocrine Therapy for Locally Advanced Breast Cancer

Seminars in Oncology

Volumn 33, Issue 6, 2006, Pages 650-656

  Ma, Cynthia X ^a   Ellis, Matthew J ^a  

^a USA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; AROMATASE INHIBITOR; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; EXEMESTANE; LETROZOLE; PACLITAXEL; PROGESTERONE; PROGESTERONE RECEPTOR; TAMOXIFEN;

ADJUVANT THERAPY; ADVANCED CANCER; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER REGRESSION; CANCER RELAPSE; CANCER SURVIVAL; CELL CYCLE REGULATION; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DRUG ACTIVITY; DRUG EFFECT; DRUG EFFICACY; ELDERLY CARE; FOLLOW UP; FRAIL ELDERLY; HUMAN; IMMUNOHISTOCHEMISTRY; MASTECTOMY; MULTIPLE CYCLE TREATMENT; PARTIAL MASTECTOMY; POSTMENOPAUSE; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, HORMONAL; AROMATASE INHIBITORS; BREAST NEOPLASMS; CLINICAL TRIALS; COMBINED MODALITY THERAPY; FEMALE; HUMANS; MASTECTOMY, SEGMENTAL; NEOADJUVANT THERAPY; NEOPLASMS, HORMONE-DEPENDENT; TIME FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 34548416486     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2006.08.013     Document Type: Article

References (35)

1. Early Breast Cancer Trialists' Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Lancet 365 (2005) 1687-1717
2. Baum M., Demicheli R., Hrushesky W., et al. Does surgery unfavourably perturb the "natural history" of early breast cancer by accelerating the appearance of distant metastases?. Eur J Cancer 41 (2005) 508-515
3. Akhtar S.S., Allan S.G., Rodger A., et al. A 10-year experience of tamoxifen as primary treatment of breast cancer in 100 elderly and frail patients. Eur J Surg Oncol 17 (1991) 30-35
4. Bradbeer J.W., and Kyngdon J. Primary treatment of breast cancer in elderly women with tamoxifen. Clin Oncol 9 (1983) 31-34
5. Horobin J.M., Preece P.E., Dewar J.A., et al. Long-term follow-up of elderly patients with locoregional breast cancer treated with tamoxifen only. Br J Surg 78 (1991) 213-217
6. Fentiman I.S., Christiaens M.R., Paridaens R., et al. Treatment of operable breast cancer in the elderly: A randomised clinical trial EORTC 10851 comparing tamoxifen alone with modified radical mastectomy. Eur J Cancer 39 (2003) 309-316
7. Kenny F.S., Robertson J.F.R., Ellis I.O., et al. Long-term follow-up of elderly patients randomized to primary tamoxifen or wedge mastectomy as initial therapy for operable breast cancer. Breast 7 (1998) 335-339
8. Gazet J.C., Ford H.T., Coombes R.C., et al. Prospective randomized trial of tamoxifen vs surgery in elderly patients with breast cancer. Eur J Surg Oncol 20 (1994) 207-214
9. Fennessy M., Bates T., MacRae K., et al. Late follow-up of a randomized trial of surgery plus tamoxifen versus tamoxifen alone in women aged over 70 years with operable breast cancer. Br J Surg 91 (2004) 699-704
10. Bates T., Riley D.L., Houghton J., et al., The Elderly Breast Cancer Working Party. Breast cancer in elderly women: A Cancer Research Campaign trial comparing treatment with tamoxifen and optimal surgery with tamoxifen alone. Br J Surg 78 (1991) 591-594
11. Mustacchi G., Milani S., Pluchinotta A., et al., Group for Research on Endocrine Therapy in the Elderly. Tamoxifen or surgery plus tamoxifen as primary treatment for elderly patients with operable breast cancer: The G.R.E.T.A. Trial. Anticancer Res 14 (1994) 2197-2200
12. Mustacchi G., Ceccherini R., Milani S., et al. Tamoxifen alone versus adjuvant tamoxifen for operable breast cancer of the elderly: Long-term results of the phase III randomized controlled multicenter GRETA trial. Ann Oncol 14 (2003) 414-420
13. Eiermann W., Paepke S., Appfelstaedt J., et al. Preoperative treatment of postmenopausal breast cancer patients with letrozole: A randomized double-blind multicenter study. Ann Oncol 12 (2001) 1527-1532
14. Smith I.E., Dowsett M., Ebbs S.R., et al. Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial. J Clin Oncol 23 (2005) 5108-5116
15. Abrial C., Mouret-Reynier M.A., Cure H., et al. Neoadjuvant endocrine therapy in breast cancer. Breast 15 (2006) 9-19
16. Cataliotti L., Buzdar A., Noguchi S., et al. Comparison of anastrozole versus tamoxifen as preoperative therapy in postmenopausal women in hormone-receptor positive breast cancer. Cancer 106 (2006) 2095-2103
17. Semiglazov V., Semiglazov V.V., Ivanov V.G., et al. Neoadjuvant endocrine therapy: exemestane vs tamoxifen in postmenopausal ER+ breast cancer patients (T1-4N1-2M0). Breast Cancer Res Treat 82 (2003) S22 (suppl 1, abstr 111)
18. Paik S., Shak S., Tang G., et al. Expression of the 21 genes in the Recurrence Score assay and prediction of clinical benefit from tamoxifen in NSABP study B-14 and chemotherapy in NSABP study B-20. Breast Cancer Res Treat 88 (2004) S16 (suppl 1, abstr 24)
19. Kuerer H.M., Newman L.A., Smith T.L., et al. Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol 17 (1999) 460-469
20. Ring A.E., Smith I.E., Ashley S., et al. Oestrogen receptor status, pathological complete response and prognosis in patients receiving neoadjuvant chemotherapy for early breast cancer. Br J Cancer 91 (2004) 2012-2017
21. Bonadonna G., Veronesi U., Brambilla C., et al. Primary chemotherapy to avoid mastectomy in tumors with diameters of three centimeters or more. J Natl Cancer Inst 82 (1990) 1539-1545
22. Mauriac L., Durand M., Avril A., et al. Effects of primary chemotherapy in conservative treatment of breast cancer patients with operable tumors larger than 3 cm. Results of a randomized trial in a single centre. Ann Oncol 2 (1991) 347-354
23. Semiglazov V.F., Semiglazov V.V., Ivanov V., et al. The relative efficacy of neoadjuvant endocrine therapy vs chemotherapy in postmenopausal women with ER- positive breast cancer. J Clin Oncol ASCO Proceedings (Post-Meeting Edition) 22 (2004) 519 (abstr)
24. Ellis M.J. Neoadjuvant endocrine therapy for breast cancer: More questions than answers. J Clin Oncol 23 (2005) 4842-4844
25. Thurlimann B., Keshaviah A., Coates A.S., et al. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 353 (2005) 2747-2757
26. Viale G., Regan M., Dell'Orto P., et al. Central review of ER, PgR and HER-2 in BIG 1-98 evaluating letrozole vs. tamoxifen as adjuvant endocrine therapy for postmenopausal women with receptor-positive breast cancer. Breast Cancer Res Treat 94 (2005) S13 (suppl 1, abstr 44)
27. Dowsett M., Ebbs S.R., Dixon J.M., et al. Biomarker changes during neoadjuvant anastrozole, tamoxifen, or the combination: influence of hormonal status and HER-2 in breast cancer-A study from the IMPACT trialists. J Clin Oncol 23 (2005) 2477-2492
28. Miller W.R., Anderson T.J., White S., et al. Aromatase inhibitors: Cellular and molecular effects. J Steroid Biochem Mol Biol 95 (2005) 83-89
29. Ellis M.J., Tao Y., Young O., et al. Estrogen-independent proliferation is present in estrogen-receptor HER2-positive primary breast cancer after neoadjuvant letrozole. J Clin Oncol 24 (2006) 3019-3025
30. Miller W.R., Anderson T.J., Hawkins R.A., et al. Neoadjuvant endocrine treatment: the Edinburgh experience. In: Howell A., and Dowsett M. (Eds). Primary Medical Therapy for Breast Cancer ESO Scientific Updates (1999), Elsevier, Amsterdam 1-11
31. Miller W.R., Krause A., Evans D.B., et al. Phenotypes for endocrine resistance can be identified by RNA microarray of sequential biopsies and are more variable than those predicting for tumour response. Breast Cancer Res Treat 94 (2005) S17 (suppl 1, abstr 31)
32. Ellis M.J., Coop A., Singh B., et al. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: Evidence from a phase III randomized trial. J Clin Oncol 19 (2001) 3808-3816
33. Allred D.C., Harvey J.M., Berardo M., et al. Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol 11 (1998) 155-168
34. Sorlie T., Perou C.M., Tibshirani R., et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 98 (2001) 10869-10874
35. Wong Z.W., and Ellis M.J. Neoadjuvant endocrine therapy for breast cancer: An over looked option?. Oncology (Williston Park) 18 (2004) 411-420